Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: April 19, 2018
Subject: Publication of the landmark IMPACT study results in the New England Journal of Medicine (NEJM) regarding Trelegy Ellipta for the treatment of Chronic Obstructive Pulmonary Disease (COPD).
Key Financial Metrics
This filing is a current report regarding clinical trial results and regulatory updates. It does not contain financial statements, revenue figures, profit margins, cash flow data, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes and Clinical Results
The filing details the publication of the IMPACT study, a Phase 3 trial involving 10,355 patients across 37 countries. Key clinical findings include:
- Primary Endpoint: Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) demonstrated superiority over dual combination therapies (Relvar/Breo and Anoro) in reducing the annual rate of moderate/severe exacerbations (p<0.001).
- Hospitalizations: A statistically significant 34% reduction in COPD hospitalizations compared to Anoro (0.13 vs. 0.19 per year; p<0.001). A 13% reduction compared to Relvar/Breo was observed but was not statistically significant (p=0.064).
- Mortality Risk: A 42.1% reduction in the risk of on-treatment all-cause mortality was observed for Trelegy compared to Anoro (1.20% vs. 1.88%; p=0.011). Management notes that off-treatment data are required to fully understand these implications.
- Safety Profile: Consistent with individual components. The incidence of pneumonia as a serious adverse event was 4% for Trelegy, 4% for Relvar/Breo, and 3% for Anoro.
Guidance, Outlook, and Risks
Regulatory Outlook: Results were submitted to US and EU authorities in late 2017 and early 2018. Further submissions in other countries are expected throughout 2018. Trelegy Ellipta is already approved in the US (September 2017) and Europe (November 2017).
Management Commentary: GSK leadership emphasizes that the study clarifies the role of inhaled corticosteroids in COPD management and provides evidence for the benefits of single-inhaler triple therapy in reducing exacerbations and improving quality of life.
Risks and Contingencies:
- Safety Warnings: Long-acting beta2-adrenergic agonists (LABA) carry a risk of asthma-related death; Trelegy is not indicated for asthma. Risks include pneumonia, adrenal suppression, bone mineral density decrease, and glaucoma.
- Forward-Looking Statements: GSK and partner Innoviva caution that future regulatory approvals and commercial results are subject to risks and uncertainties that may cause actual results to differ materially from projections.
Investor Verification Checklist
- Verify the status of regulatory submissions for Trelegy Ellipta in markets outside the US and EU expected in 2018.
- Monitor upcoming scientific meetings for the release of off-treatment mortality data to fully assess the 42.1% mortality reduction claim.
- Review the full US Prescribing Information for detailed safety warnings regarding pneumonia and adrenal function.
- Assess the commercial impact of the IMPACT study on the sales trajectory of Trelegy Ellipta versus existing dual therapies (Relvar/Breo and Anoro).
- Confirm the terms of the partnership with Innoviva, Inc., specifically regarding royalty revenues and the 15% economic interest retained by Innoviva.